<DOC>
	<DOCNO>NCT02026934</DOCNO>
	<brief_summary>CliniMACs investigational device use select enrich stem cell . The device select stem cell CD34+ protein . The participant infuse CD34+ select cell hop help participant engraft . Engraftment transplant stem cell resume production healthy blood cell .</brief_summary>
	<brief_title>CliniMACSÂ® CD34+ Reagent System Expanded Access Use</brief_title>
	<detailed_description>- After screen procedure confirm participant eligible participate research study : If participant take part research study , participant ( donor ) follow test procedure : - Donor Graft Collection : The participant 's cell donor undergo stem cell collection . The cell collect sent laboratory processing . - Donor Graft Processing : In laboratory CliniMACS device use separate CD34+ stem cell type cell graft . After complete necessary safety test , CD34+ select donor graft ready administration . - Donor Graft Infusion : The CD34+ select donor graft infuse intravenous ( I.V . ) catheter . The day infusion call Day 0 . - Follow-Up Visits : Approximately 3 , 6 12 month donor graft infusion , participant return clinic follow-up visit . At visit , participant physical exam ask question general health . The participant also routine blood test perform ( approximately 1 tablespoon blood ) . - At time cell collect donation need transplantation . If physician determines preferable administer dose cell less complete collection , extra cell may freeze store freezer participant 's future use . If cell count improve , participant give remain cell intravenous ( I.V . ) catheter .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Delayed Graft Function</mesh_term>
	<criteria>Patients age &gt; 18 year Diagnosis graft exhaustion . Ability understand willingness sign write informed consent document Matched relate unrelated donor must consent provide allograft . Symptomatic uncontrolled cardiac failure coronary artery disease . Karnofsky performance status &lt; 60 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Graft-Versus-Host Disease ( GVHD )</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation .</keyword>
	<keyword>Graft failure</keyword>
	<keyword>Graft exhaustion</keyword>
</DOC>